# Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation

> **NCT04131738** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 26 (actual)

## Conditions studied

- Graft-versus-host-disease
- Graft Vs Host Disease

## Interventions

- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT04131738
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-07
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-08-17
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04131738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04131738, "Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04131738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*